5.33
-0.16 (-2.91%)
| Previous Close | 5.49 |
| Open | 5.66 |
| Volume | 48,789 |
| Avg. Volume (3M) | 58,142 |
| Market Cap | 56,501,220 |
| Price / Earnings (TTM) | 44.42 |
| Price / Sales | 2.97 |
| Price / Book | 5.12 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 5.16% |
| Operating Margin (TTM) | 11.60% |
| Diluted EPS (TTM) | 0.080 |
| Quarterly Revenue Growth (YOY) | 38.50% |
| Total Debt/Equity (MRQ) | 14.28% |
| Current Ratio (MRQ) | 5.92 |
| Operating Cash Flow (TTM) | -2.03 M |
| Levered Free Cash Flow (TTM) | -1.57 M |
| Return on Assets (TTM) | 4.16% |
| Return on Equity (TTM) | 9.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Nephros, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 11.19% |
| % Held by Institutions | 44.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mesirow Financial Investment Management, Inc. | 30 Jun 2025 | 13,800 |
| 52 Weeks Range | ||
| Median | 6.00 (12.57%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Maxim Group | 08 Aug 2025 | 6.00 (12.57%) | Buy | 3.90 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Oct 2025 | Announcement | Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water |
| 07 Aug 2025 | Announcement | Nephros Announces Strong Second Quarter Financial Results |
| 31 Jul 2025 | Announcement | Nephros Schedules Second Quarter 2025 Financial Results Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |